Berger Miles, Nadler Jacob W, Friedman Allan, McDonagh David L, Bennett Ellen R, Cooter Mary, Qi Wenjing, Laskowitz Daniel T, Ponnusamy Vikram, Newman Mark F, Shaw Leslie M, Warner David S, Mathew Joseph P, James Michael L
Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
Division Chief, Neurosurgical Anesthesiology Medical Director, Postanesthesia Care Unit; Department of Anesthesiology, University of Rochester, Rochester, NY, USA.
J Alzheimers Dis. 2016 Apr 15;52(4):1299-310. doi: 10.3233/JAD-151190.
Preclinical studies have found differential effects of isoflurane and propofol on the Alzheimer's disease (AD)-associated markers tau, phosphorylated tau (p-tau) and amyloid-β (Aβ).
We asked whether isoflurane and propofol have differential effects on the tau/Aβ ratio (the primary outcome), and individual AD biomarkers. We also examined whether genetic/intraoperative factors influenced perioperative changes in AD biomarkers.
Patients undergoing neurosurgical/otolaryngology procedures requiring lumbar cerebrospinal fluid (CSF) drain placement were prospectively randomized to receive isoflurane (n = 21) or propofol (n = 18) for anesthetic maintenance. We measured perioperative CSF sample AD markers, performed genotyping assays, and examined intraoperative data from the electronic anesthesia record. A repeated measures ANOVA was used to examine changes in AD markers by anesthetic type over time.
The CSF tau/Aβ ratio did not differ between isoflurane- versus propofol-treated patients (p = 1.000). CSF tau/Aβ ratio and tau levels increased 10 and 24 h after drain placement (p = 2.002×10-6 and p = 1.985×10-6, respectively), mean CSF p-tau levels decreased (p = 0.005), and Aβ levels did not change (p = 0.152). There was no interaction between anesthetic treatment and time for any of these biomarkers. None of the examined genetic polymorphisms, including ApoE4, were associated with tau increase (n = 9 polymorphisms, p > 0.05 for all associations).
Neurosurgery/otolaryngology procedures are associated with an increase in the CSF tau/Aβ ratio, and this increase was not influenced by anesthetic type. The increased CSF tau/Aβ ratio was largely driven by increases in tau levels. Future work should determine the functional/prognostic significance of these perioperative CSF tau elevations.
临床前研究发现异氟烷和丙泊酚对阿尔茨海默病(AD)相关标志物tau、磷酸化tau(p-tau)和淀粉样β蛋白(Aβ)有不同影响。
我们探讨异氟烷和丙泊酚对tau/Aβ比值(主要结局)及个体AD生物标志物是否有不同影响。我们还研究了基因/术中因素是否会影响AD生物标志物的围手术期变化。
对因神经外科/耳鼻喉科手术需要放置腰椎脑脊液(CSF)引流管的患者进行前瞻性随机分组,分别接受异氟烷(n = 21)或丙泊酚(n = 18)进行麻醉维持。我们测量围手术期CSF样本中的AD标志物,进行基因分型检测,并检查电子麻醉记录中的术中数据。采用重复测量方差分析来研究不同麻醉类型下AD标志物随时间的变化。
异氟烷治疗组和丙泊酚治疗组患者的CSF tau/Aβ比值无差异(p = 1.000)。引流管放置后10小时和24小时,CSF tau/Aβ比值和tau水平升高(分别为p = 2.002×10 - 6和p = 1.985×10 - 6),平均CSF p-tau水平降低(p = 0.005),Aβ水平无变化(p = 0.152)。对于这些生物标志物中的任何一种,麻醉治疗与时间之间均无相互作用。所检测的基因多态性,包括载脂蛋白E4(ApoE4),均与tau升高无关(n = 9种多态性,所有关联的p均>0.05)。
神经外科/耳鼻喉科手术与CSF tau/Aβ比值升高有关,且这种升高不受麻醉类型的影响。CSF tau/Aβ比值升高主要是由tau水平升高驱动的。未来的研究应确定这些围手术期CSF tau升高在功能/预后方面的意义。